Welcome to LookChem.com Sign In|Join Free
  • or
3-bromopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1094101-31-1

Post Buying Request

1094101-31-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1094101-31-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1094101-31-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,4,1,0 and 1 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1094101-31:
(9*1)+(8*0)+(7*9)+(6*4)+(5*1)+(4*0)+(3*1)+(2*3)+(1*1)=111
111 % 10 = 1
So 1094101-31-1 is a valid CAS Registry Number.

1094101-31-1Relevant academic research and scientific papers

Twin medicine type HMG-CoA reductase inhibiting agent and synthesis method thereof

-

Paragraph 0022; 0023; 0024; 0055; 0056; 0057, (2017/10/18)

The invention belongs to the technical field of medicine chemistry, and particularly relates to a first-class twin medicine type HMG-CoA reductase inhibiting agent and a synthesis method thereof. The preparation method of the novel twin medicine type HMG-CoA reductase inhibiting agent has the advantages that the reaction steps are simple; no pollution exists; the method is suitable for industrial scaled application; the activity of the HMG-CoA reductase inhibiting agent is obviously superior to that of positive control medicine.

COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS

-

Page/Page column 46-47, (2009/01/23)

Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more fibric acid or statin derivative compositions alone or in combination with one or more lipid altering agents and/or PDE inhibitors.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1094101-31-1